A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
for Secondary Progressive Multiple Sclerosis (SPMS)
36 locations incl. Birmingham
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 65
Code: NCT07225504·Phase 3·Recruiting·Listed Nov 2025